Cytek Biosciences Stock Performance
| CTKB Stock | USD 5.12 0.08 1.54% |
On a scale of 0 to 100, Cytek Biosciences holds a performance score of 10. The firm shows a Beta (market volatility) of -0.23, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Cytek Biosciences are expected to decrease at a much lower rate. During the bear market, Cytek Biosciences is likely to outperform the market. Please check Cytek Biosciences' expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to make a quick decision on whether Cytek Biosciences' price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cytek Biosciences are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating forward-looking signals, Cytek Biosciences sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.38) | Five Day Return (7.00) | Year To Date Return 5.28 | Ten Year Return (72.39) | All Time Return (72.39) |
1 | Piper Sandler Maintains Cytek Biosciences Overweight Recommendation - Nasdaq | 11/11/2025 |
2 | Acquisition by Chin Richard of 6107 shares of Cytek Biosciences subject to Rule 16b-3 | 11/18/2025 |
3 | Disposition of 2032 shares by William McCombe of Cytek Biosciences at 5.53 subject to Rule 16b-3 | 11/28/2025 |
4 | PNC Financial Services Group Inc. Has 56,000 Stock Holdings in Cytek Biosciences, Inc. CTKB | 12/02/2025 |
5 | Disposition of 29002 shares by Wenbin Jiang of Cytek Biosciences subject to Rule 16b-3 | 12/03/2025 |
6 | Brown Capital Management LLC Has 24.17 Million Stock Position in Cytek Biosciences, Inc. CTKB - MarketBeat | 12/05/2025 |
7 | Is Cytek Biosciences Inc. stock at risk of policy regulation - Trade Ideas High Accuracy Trade Signal Alerts - DonanmHaber | 12/19/2025 |
8 | What risks investors should watch in Cytek Biosciences Inc stock - Gap Down Free Safe Capital Growth Stock Tips - moha.gov.vn | 12/31/2025 |
| Begin Period Cash Flow | 167.6 M | |
| Total Cashflows From Investing Activities | -83 M |
Cytek Biosciences Relative Risk vs. Return Landscape
If you would invest 382.00 in Cytek Biosciences on October 30, 2025 and sell it today you would earn a total of 138.50 from holding Cytek Biosciences or generate 36.26% return on investment over 90 days. Cytek Biosciences is currently generating 0.5993% in daily expected returns and assumes 4.4287% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Cytek, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cytek Biosciences Target Price Odds to finish over Current Price
The tendency of Cytek Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 5.12 | 90 days | 5.12 | about 40.66 |
Based on a normal probability distribution, the odds of Cytek Biosciences to move above the current price in 90 days from now is about 40.66 (This Cytek Biosciences probability density function shows the probability of Cytek Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Cytek Biosciences has a beta of -0.23 suggesting as returns on the benchmark increase, returns on holding Cytek Biosciences are expected to decrease at a much lower rate. During a bear market, however, Cytek Biosciences is likely to outperform the market. Additionally Cytek Biosciences has an alpha of 0.4304, implying that it can generate a 0.43 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Cytek Biosciences Price Density |
| Price |
Predictive Modules for Cytek Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cytek Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Cytek Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cytek Biosciences is not an exception. The market had few large corrections towards the Cytek Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cytek Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cytek Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.43 | |
β | Beta against Dow Jones | -0.23 | |
σ | Overall volatility | 0.55 | |
Ir | Information ratio | 0.08 |
Cytek Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cytek Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cytek Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cytek Biosciences appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 200.45 M. Net Loss for the year was (6.02 M) with profit before overhead, payroll, taxes, and interest of 105.23 M. | |
| About 63.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: What risks investors should watch in Cytek Biosciences Inc stock - Gap Down Free Safe Capital Growth Stock Tips - moha.gov.vn |
Cytek Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cytek Stock often depends not only on the future outlook of the current and potential Cytek Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cytek Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 130.6 M | |
| Cash And Short Term Investments | 277.9 M |
Cytek Biosciences Fundamentals Growth
Cytek Stock prices reflect investors' perceptions of the future prospects and financial health of Cytek Biosciences, and Cytek Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cytek Stock performance.
| Return On Equity | -0.0336 | ||||
| Return On Asset | -0.0436 | ||||
| Profit Margin | (0.07) % | ||||
| Operating Margin | (0.18) % | ||||
| Current Valuation | 425.43 M | ||||
| Shares Outstanding | 127.86 M | ||||
| Price To Book | 1.75 X | ||||
| Price To Sales | 3.37 X | ||||
| Revenue | 200.45 M | ||||
| Gross Profit | 105.23 M | ||||
| EBITDA | (10.03 M) | ||||
| Net Income | (6.02 M) | ||||
| Cash And Equivalents | 349.89 M | ||||
| Cash Per Share | 2.60 X | ||||
| Total Debt | 17.02 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 10.47 X | ||||
| Book Value Per Share | 2.96 X | ||||
| Cash Flow From Operations | 25.38 M | ||||
| Earnings Per Share | (0.11) X | ||||
| Market Capitalization | 662.34 M | ||||
| Total Asset | 499.5 M | ||||
| Retained Earnings | (35.2 M) | ||||
| Working Capital | 328.78 M | ||||
About Cytek Biosciences Performance
By analyzing Cytek Biosciences' fundamental ratios, stakeholders can gain valuable insights into Cytek Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cytek Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cytek Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 206.21 | 256.50 | |
| Return On Tangible Assets | (0.01) | (0.01) | |
| Return On Capital Employed | (0.04) | (0.04) | |
| Return On Assets | (0.01) | (0.01) | |
| Return On Equity | (0.01) | (0.01) |
Things to note about Cytek Biosciences performance evaluation
Checking the ongoing alerts about Cytek Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cytek Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cytek Biosciences appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 200.45 M. Net Loss for the year was (6.02 M) with profit before overhead, payroll, taxes, and interest of 105.23 M. | |
| About 63.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: What risks investors should watch in Cytek Biosciences Inc stock - Gap Down Free Safe Capital Growth Stock Tips - moha.gov.vn |
- Analyzing Cytek Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cytek Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Cytek Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cytek Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cytek Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cytek Biosciences' stock. These opinions can provide insight into Cytek Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cytek Stock analysis
When running Cytek Biosciences' price analysis, check to measure Cytek Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytek Biosciences is operating at the current time. Most of Cytek Biosciences' value examination focuses on studying past and present price action to predict the probability of Cytek Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytek Biosciences' price. Additionally, you may evaluate how the addition of Cytek Biosciences to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |